Psychosis in Parkinson’s disease: identification, prevention and treatment

Journal of Neural Transmission

Volumn 123, Issue 1, 2016, Pages 45-50

  Levin, Johannes ^a   Hasan, Alkomiet ^b   Höglinger, Günter U ^c,d  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Dopamine; Hallucination; Parkinson s disease; Psychosis

Indexed keywords

ANTIPARKINSON AGENT; CHOLESTEROL ESTERASE; HYPOCHOLESTEROLEMIC AGENT;

AVOIDANCE BEHAVIOR; DISEASE DURATION; HUMAN; MEDICAL DOCUMENTATION; PARKINSON DISEASE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SYMPTOMATOLOGY; COMPLICATION; DISEASE MANAGEMENT; PSYCHOTIC DISORDERS;

ANTICHOLESTEREMIC AGENTS; ANTIPARKINSON AGENTS; DISEASE MANAGEMENT; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS; RISK FACTORS;

EID: 84955204369     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-015-1400-x     Document Type: Review

References (34)

1. Bizzarri JV, Giupponi G, Maniscalco I, Schroffenegger P, Conca A, Kapfhammer HP (2015) Parkinson’s disease and psychoses. Neuropsychiatr. (Epub ahead of print)
2. Carod-Artal FJ, Mesquita HM, Ziomkowski S, Martinez-Martin P (2013) Burden and health-related quality of life among caregivers of Brazilian Parkinson’s disease patients. Parkinsonism Relat Disord 19:943–948. doi:10.1016/j.parkreldis.2013.06.005
3. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911
4. Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–1683. doi:10.1001/jama.2014.3654
5. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540. doi:10.1016/S0140-6736(13)62106-6
6. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2008) Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 23:484–500. doi:10.1002/mds.21875
7. Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract 24:534–540. doi:10.1177/0897190011426556
8. Gama RL, de Bruin VM, de Bruin PF, Távora DG, Lopes EM, Jorge IF, Bittencourt LR, Tufik S (2015) Risk factors for visual hallucinations in patients with Parkinson’s disease. Neurol Res 37:112–116. doi:10.1179/1743132814Y.0000000418
9. Godschalx-Dekker JA, Siegers HP (2014) Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry 47:81–83. doi:10.1055/s-0034-1367014
10. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229
11. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 22:41–47
12. Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 16:281. doi:10.1007/s11940-013-0281-2
13. Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, Malaty IA, Romrell J, Shukla AA, McFarland N, Ward HE, Okun MS (2014) An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting. PLoS ONE 9(3):e91545. doi:10.1371/journal.pone.0091545
14. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378
15. Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, Giladi N, Bloem BR, Malaty IA, Okun MS, Investigators NPF-QII (2013) High rates and the risk factors for emergency room visits and hospitalization in Parkinson’s disease. Parkinsonism Relat Disord 19:949–954. doi:10.1016/j.parkreldis.2013.06.006
16. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35(3):549–562. doi:10.1093/schbul/sbp006
17. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360–369
18. Lee AH, Weintraub D (2012) Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 27:858–863. doi:10.1002/mds.25003
19. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962. doi:10.1016/S0140-6736(13)60733-3
20. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 183:144–153
21. Lutz UC, Sirfy A, Wiatr G, Altpass D, Farger G, Gasser T, Karle KN, Batra A (2014) Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol 70:1471–1476. doi:10.1007/s00228-014-1772-0
22. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177–197. doi:10.1016/S0079-6123(08)00909-6
23. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res 141:144–152. doi:10.1016/j.schres.2012.07.029
24. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454–1456
25. Rodríguez-Violante M, Cervantes-Arriaga A, Velázquez-Osuna S, Llorens-Arenas R, Calderón-Fajardo H, Piña-Fuentes D, Martinez-Martin P (2014) Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinsons Dis 2014:260485. doi:10.1155/2014/260485
26. Sawada H, Oeda T (2013) Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP). BMJ Open 3:e003533. doi:10.1136/bmjopen-2013-003533
27. Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T (2013) Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol 13:145. doi:10.1186/1471-2377-13-145
28. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80. doi:10.1002/mds.23884
29. Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111–115. doi:10.1097/YCT.0b013e3181c18a3d
30. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H (2011) Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 35:1704–1708. doi:10.1016/j.pnpbp.2011.05.003
31. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H (2013) Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord 19:295–299. doi:10.1016/j.parkreldis.2012.10.022
32. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68:899–904. doi:10.1001/archneurol.2011.139
33. Whitehouse PJ (1987) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 45:393–397
34. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10–S13